Free Trial
NASDAQ:DBVT

DBV Technologies Q4 2024 Earnings Report

DBV Technologies logo
$8.95 +0.34 (+3.95%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$8.76 -0.19 (-2.12%)
As of 05/2/2025 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DBV Technologies EPS Results

Actual EPS
-$1.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

DBV Technologies Revenue Results

Actual Revenue
$0.51 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

DBV Technologies Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

DBV Technologies' Q1 2025 earnings is scheduled for Tuesday, May 6, 2025, with a conference call scheduled on Friday, May 9, 2025 at 11:40 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

DBV Technologies Earnings Headlines

DBV Technologies (NASDAQ:DBVT) Price Target Raised to $15.00
Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
See More DBV Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like DBV Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DBV Technologies and other key companies, straight to your email.

About DBV Technologies

DBV Technologies (NASDAQ:DBVT), a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

View DBV Technologies Profile

More Earnings Resources from MarketBeat